CCMI

CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction[1].

Product Specifications

CAS Number

[917837-54-8]

Product Name Alternative

AVL-3288; UCI-4083

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ccmi.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(Cl)C=C1)/C(C2=CC(C)=NO2)=C/NC3=CC=C(Cl)C=C3

Molecular Formula

C19H15Cl2N3O2

Molecular Weight

388.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Ng HJ, et al. Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci U S A. 2007 May 8;104 (19) :8059-64. Epub 2007 Apr 30.